Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]JAB-21822 in Healthy Male Subjects
NCT05920941Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glecirasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by Allist Pharmaceuticals. Primary endpoints: Recovery of total radioactivity in urine and fecal samples, Total radioactivity in plasma PK: Cmax and 6 more. Started Jul 2023; status: completed.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05920941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920941.